Boundless Bio, Inc. Common Stock

Day range

$2.45 – $2.59

Open

$2.53

Prev close

$2.48

Volume

9.83K

Market cap

$57.31M

Shares out

22.75M

P/E

—

P/S

—

P/B

0.87

P/FCF

—

ROE

-97.0%

ROA

-86.8%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 29, 2026

• Private placementJun 23, 2026

  In connection with the execution and delivery of the Merger Agreement, certain institutional and accredited investors entered into a Series A stock purchase agreement with Serapha, pursuant to which such persons invested in a private placement of Serapha's Series A preferred stock for an aggregate purchase price of approximately $138,000,000.

• Annual meeting resultsJun 17, 2026

  At the annual meeting of stockholders of Boundless Bio, Inc. (the Company) held on June 15, 2026 (the Meeting), two proposals were voted upon by the Company's stockholders... Each of the director nominees was elected as a Class II director to hold office until the Company's 2029 annual meeting of stockholders.

• Deal terminationApr 13, 2026

  On April 13, 2026, Boundless Bio, Inc. (the "Company") entered into an Agreement for Termination of Lease and Voluntary Surrender of Premises (the "Lease Termination Agreement") with ARE-10933 North Torrey Pines, LLC ("Landlord"), pursuant to which the Company and Landlord agreed to terminate that certain Lease Agreement dated as of December 20, 2021, as amended by that certain First Amendment to Lease dated as of November 1, 2024 (as amended, the "Lease").

• Director departureMar 9, 2026

  Effective March 3, 2026, Christine Brennan, Ph.D. notified the Company of her resignation from the Board of Directors of the Company. Dr. Brennan's resignation was made in connection with her assuming a new role at Johnson & Johnson Development Corporation, and was not the result of any disagreement with the Company.

• Annual meeting resultsJun 23, 2025

  At the annual meeting of stockholders of Boundless Bio, Inc. (the Company) held on June 23, 2025 (the Meeting), two proposals were voted upon by the Company's stockholders... Below is a brief description of, and the final results of the votes for, each proposal.

Days to cover

4.6

Short interest

788.48K

Avg volume

170.58K

As of Oct 15, 2026 · reported to FINRA twice monthly.

• Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
  positiveGlobeNewswire Inc.· Apr 17, 2026
• Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
  positiveGlobeNewswire Inc.· Mar 9, 2026
• Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
  positiveGlobeNewswire Inc.· Feb 5, 2026
• Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights
  positiveGlobeNewswire Inc.· May 9, 2025
• Boundless Bio to Participate in the Needham Virtual Healthcare Conference
  positiveGlobeNewswire Inc.· Apr 3, 2025